KRAS Mutation
Real-Time PCR Detection Kit
KRAS Mutation Real-Time PCR Detection Kit is an in vitro qualitative kit for the detection of seven somatic mutations located at codon 12 and 13 of KRAS gene in the human genomic DNA extracted from paraffin embedded tissue sections or liquid biopsy samples. The kit is designed to selectively amplify mutant specific sequences in samples that contain a mixture of wild-type and mutated KRAS DNA samples.
SKU
-
100 Rxns - NDXIVD003
-
50 Rxns - NDXIVD003_01
-
20 Rxns -NDXIVD003_02
Features & Benefits:
-
Kit Format & Chemistry: Single-Tube, Multiplex Real-Time PCR Assay based on Taqman-probe-based Chemistry
-
Target: LNA-based for detection of JAK2 (Janus Kinase 2) V617F allele in genomic DNA against a background of Wild Type Allele.
-
Internal Control: Beta Actin
-
LoD /Analytical sensitivity: 10 copies/uL
-
PCR Run time: <90 Minutes
-
Sample Compatibility: DNA extracted from Whole Blood EDTA.
-
RT-PCR: Open-System Platform; Instruments with FAM, Texas Red/ROX Channels
-
Standardized: WHO International standards - NIBSC 16/120
Storage & Precautions
-
Recommended Storage: -20°C
-
For Professional Use only.
-
Read user manual
Clinical Relevance
JAK2 V617F is a somatic point mutation in the Janus Kinase 2 gene that results in constitutive activation of the JAK-STAT signaling pathway, independent of normal regulatory control. This uncontrolled signaling promotes excessive proliferation and survival of myeloid lineage cells, leading to the development of myeloproliferative neoplasms (MPNs). The JAK2 V617F mutation is the most common genetic abnormality in MPNs and is detected in approximately 95% of patients with Polycythemia Vera (PV) and in 50–60% of patients with Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). Detection of the JAK2 V617F mutation serves as a critical diagnostic and classification marker for MPNs, helps differentiate clonal myeloproliferation from reactive conditions, and supports disease diagnosis, prognosis, and therapeutic decision-making.
